Should also note that the study missed its primary endpoint, but the companies decided to wait for the 18 month analysis anyway, and one dose seemed promising a

Should also note that the study missed its primary endpoint, but the companies decided to wait for the 18 month analysis anyway, and one dose seemed promising at this 18 month timepiint. Other doses did worse than placebo Other analysts who have been looking forward to the data and have digested it in detail have similar takes, others more positive: https://www.fiercebiotech.com/biotech/biogen-and-eisai-s-anti-amyloid-med-slows-alzheimer-s-decline-phase-2 https://www.fiercebiotech.com/biotech/biogen-and-eisai-s-ant... APOE4 status was an issue. Also the fact that two doses did worse than placebo was odd. And one of the measures of cognitive decline was a metric developed by the company, which could be concerning or could be valid, idk